An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma. Salles, G. A., Gopal, A. K., Martin, P., Marcus, R., Hess, G., Zinzani, P., Ahmadi, T., Zhuang, S., Levy, R. AMER SOC CLINICAL ONCOLOGY. 2013

View details for Web of Science ID 000335419605519